Drug
Resistance
Testing
in
HIV-1
Infection
By
Daniel
R.
Kuritzkes,
MD
Director
of
AIDS
Research,
Brigham
and
Women's
Hospital
Associate
Professor
of
Medicine,
Harvard
Medical
School
Clinical
Significance
of
Drug
Resistance
in
HIV-1
Infection
Genotype
and
Phenotype
How
Resistance
Tests
are
Done
Genotypic
Assays
Phenotypic
Assays
Genotyping
vs
Phenotyping:
Advantages
and
Disadvantages
Interpreting
Resistance
Tests
The
Virtual
Phenotype
Prognostic
Value
of
Resistance
Testing
Prospective
Trials
of
Drug
Resistance
Testing
Full
Report
on
Laboratory
Tests
for
HIV-
Infection
Selected
Highlights
from
the
XIV
International
HIV
Drug
Resistance Workshop
June
7-11,
2005,
Quebec
City,
Quebec,
Canada
-
Introduction
-
Workshop
Summary
Report:
Parts
1-3
Parts
4-5
-
CCR5
Entry
Antagonists
(Entry
Inhibitors)
-
Fusion
(entry)
Inhibitors
-
Phenotypic
Resistance
Testing
-
Genotypic
Resistance
Testing
-
Protease
Inhibitors
/ Boosted
PIs
-
Nucleoside/tide
Analogue
Reverse
Transcriptase
Inhibitors
-
Non
Nucleoside
Reverse
Transcriptase
Inhibitors
- Replication
Capacity
Articles
on
Genotype
Resistance
Testing
Articles
on
Phenotype
Resistance
Testing
Articles
on
Replication
Capacity
Tests
Articles
on
Resistance
Testing
(General)
|
